---
title: "Novo Nordisk A/S (NVO.US) — 公司概況"
type: "Symbol"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/quote/NVO.US/overview.md"
symbol: "NVO.US"
name: "Novo Nordisk A/S"
parent: "https://longbridge.com/zh-HK/quote/NVO.US.md"
datetime: "2026-04-17T08:47:38.025Z"
locales:
  - [en](https://longbridge.com/en/quote/NVO.US/overview.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/NVO.US/overview.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/NVO.US/overview.md)
---

# Novo Nordisk A/S (NVO.US) — 公司概況

## 基本資訊

| 項目 | 詳情 |
|------|--------|
| 行業 | 制藥 |
| 交易所 | US Market |
| 地址 | Novo Alle 1, Bagsvaerd, Capital Region of Denmark, Denmark |
| 官網 | [www.novonordisk.com](https://www.novonordisk.com) |

## 公司簡介

諾和諾德公司（Novo Nordisk A/S）及其子公司從事藥品的研究與開發、生產和分銷。公司通過兩個業務部門運營：肥胖與糖尿病護理以及罕見疾病。肥胖與糖尿病護理部門提供糖尿病、肥胖、心血管及其他新興治療領域的產品。罕見疾病部門則提供罕見血液疾病、罕見內分泌疾病和激素替代療法領域的產品

## 核心管理層

| 名稱 | 職位 |
|------|-------|
| Karsten Munk Knudsen | Executive VP, CFO & Member of the Management Board |
| Lars Rebien Sorensen | Chair of Board |
| Maziar Mike Doustdar | President, CEO & Member of the Management Board |
| Martin Holst Lange | EVP of R&D, Chief Scientific Officer and Member of the Management Board |
| Tania Sabroe | EVP of People, Organisation and Corporate Affairs & Member of Management Board |
| Thilde Hummel Bogebjerg | Executive VP of Enterprise IT & Quality and Member of Management Board |
| Cornelis de Jong | Independent Vice Chair of the Board |
| Stephan Engels | Independent Director |
| Desirée Jantzen Asgreen | Employee Representative Director |
| Mette Bojer Jensen | Employee Non-Independent Representative Director |

## 主要股東

| 名稱 | 佔比 | 報告日期 |
|------|-------|-------------|
| Novo Holdings A/S | 28.23% | 2025-02-04 |
| BlackRock, Inc. | 4.08% | 2025-12-31 |
| The Vanguard Group, Inc. | 3.27% | 2026-02-28 |
| Norges Bank Investment Management | 1.61% | 2025-12-31 |
| Amundi Asset Management SAS | 0.62% | 2025-12-31 |
| Geode Capital Management, LLC | 0.60% | 2026-03-31 |
| State Street Global Advisors, Inc. | 0.41% | 2026-03-31 |
| JP Morgan Asset Management | 0.41% | 2026-03-31 |
| Loomis Sayles & Company, L.P. | 0.40% | 2026-01-31 |
| Deutsche Asset & Wealth Management | 0.40% | 2026-01-31 |

## 業務構成

| 業務線 | 營收 | 佔比 |
|---------|---------|-------|
| 糖尿病和肥胖護理 | 289456000000 | 93.66% |
| 罕見病 | 19608000000 | 6.34% |

```vega-lite
{
  "$schema": "https://vega.github.io/schema/vega-lite/v5.json",
  "title": "Novo Nordisk A/S Business Breakdown",
  "data": {
    "values": [
      {
        "segment": "糖尿病和肥胖護理",
        "ratio": 93.66
      },
      {
        "segment": "罕見病",
        "ratio": 6.34
      }
    ]
  },
  "mark": "arc",
  "encoding": {
    "theta": {
      "field": "ratio",
      "type": "quantitative"
    },
    "color": {
      "field": "segment",
      "type": "nominal"
    }
  }
}
```

## 地區分佈

| 地區 | 營收 | 佔比 |
|--------|---------|-------|
| 美國 | 173166000000 | 56.03% |
| 歐洲和加拿大 | 66091000000 | 21.38% |
| 新興市場 | 30436000000 | 9.85% |
| 亞太 | 20713000000 | 6.7% |
| Region China | 18658000000 | 6.04% |


---

> **免責聲明: 本文僅供參考，不構成任何投資建議。**